



Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors

South San Francisco, Calif., September 27, 2018 – Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Deborah (Debbie) M. Messemer to the Company's Board of Directors. Ms. Messemer has more than 30 years of experience providing financial expertise to public and private companies and was the Managing Partner of KPMG's Bay Area and Northwest region until her recent retirement.

"Debbie is a seasoned executive with deep financial and audit experience. She also served as the senior account executive for some of KPMG's largest and most prominent clients," said Arie Beldegrun, M.D., FACS, Executive Chairman and Co-Founder of Allogene. "As Allogene continues to progress, Debbie's financial expertise and applied understanding of our stage of growth will play an important role on our Board."

Ms. Messemer, a certified public accountant (CPA), joined KPMG LLP, the U.S. member firm of KPMG International, in 1982 and was admitted into partnership in 1995. As Managing Partner for the Bay Area and Northwest region, she was responsible for leading over 3,000 team members in 10 offices across all functions, including audit, tax and advisory. Ms. Messemer spent the majority of her career in KPMG's audit practice as an audit engagement partner serving public and private clients in a variety of industry sectors. In addition to audit signing responsibilities, Ms. Messemer has significant experience in SEC filings, due diligence, initial public offerings, mergers and acquisitions, and internal controls over financial reporting.

"I was drawn to this opportunity to serve on Allogene's Board of Directors because of its life-changing mission and its world-class management team that has demonstrated the ability to innovate cutting-edge cancer therapies," said Ms. Messemer.

Ms. Messemer was honored as the Financial Woman of the Year by the Financial Women of San Francisco (FWSF) in 2016 and was named as one of the Bay Area's Most Influential Women in Business by the San Francisco Business Times.

Ms. Messemer is a member of the National Association of Corporate Directors (NACD) and of the San Francisco Chapter of Women Corporate Directors (WCD). She has served extensively on non-profit and advisory boards including the Bay Area Council, the San Francisco Committee on Jobs, the California Chamber of Commerce, the San Francisco Chamber of Commerce, the UC Berkeley Fisher Center Policy Advisory Board, San Francisco Ballet, and Posse. She is a member of the International Women's Forum and Leadership San Francisco, Class of 2001. She received a bachelor's degree in accounting from the University of Texas at Arlington.

Allogene is advancing its AlloCAR T™ cell portfolio, which includes rights to 16 preclinical CAR T cell therapy targets and U.S. rights to UCART19, an AlloCAR T™ cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. In

partnership with Servier, UCART19 is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.

AlloCAR T™ cell therapies are engineered from cells of healthy donors, which is intended to allow for creation of inventory for on demand use in patients. This approach is designed to eliminate the need to create personalized therapy from a patient’s own cells, simplify manufacturing, and reduce the time patients must wait for CAR T cell treatment. The Allogene portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an AlloCAR T™ therapy candidate currently in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

#

Allogene Media/Investor Contact:

Christine Cassiano

Chief Communications Officer

(714) 552-0326

Christine.Cassiano@allogene.com